FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310108059> ?p ?o ?g. }

• W4310108059 endingPage "3198" @default.
• W4310108059 startingPage "3196" @default.
• W4310108059 abstract "Background:FLT3 mutations (FLT3m) are detected in approximately 30% of newly diagnosed (ND) pts with AML and are associated with poor prognosis. FLT3m can also emerge in relapse in pts with previously wild-type FLT3 AML; however, their frequency and clinical implications are not well studied. Our objective was to identify pts who relapsed with emergent FLT3m and compare their clinical and pathological characteristics to those who relapse without FLT3m. Methods: We identified 686 pts with ND AML treated at our institution between 12/2005 and 01/2020, who achieved complete remission (CR) / CR with incomplete count recovery (CRi) and subsequent relapse of AML. Pts with available FLT3 status (ITD and TKD) at diagnosis and within 4 weeks of first relapse were included (N=300). A multiplex fluorescent-based PCR analysis followed by capillary electrophoresis for detection of FLT3 ITD and/or TKD was performed on DNA isolated from BM aspirate samples. Next-generation sequencing (NGS) at baseline was performed using the Illumina MiSeq platform with multigene panels (either 28-gene, 53-gene, or 81-gene) interrogating genes recurrently mutated in myeloid neoplasms. Results: Among 300 pts who achieved CR/CRi after induction and eventually relapsed, 216 (72%) had FLT3 wild-type (WT) AML and 84 (28%) had FLT3m AML at diagnosis. Baseline clinical features are shown in Table 1. 43 (14%) pts had a change of FLT3 status between baseline and relapse: 30 pts had FLT3m at baseline that wasn't detected at relapse, and 13 pts with FLT3 WT AML at baseline experienced relapse with FLT3m AML. The median remission duration (until 1st relapse) for the entire study cohort pts withFLT3 WT and pts with FLT3m AML was 7.8 months (range, 0.2-147.2), 9 months (0.2-147.2), and 6.1 months (range, 0.5-79.6), respectively. FLT3 wild-type at Diagnosis Among 216 pts with FLT3 WT AML at baseline, 203 (94%) and 13 (6%) experienced relapse with FLT3 wild-type and FLT3m AML, respectively. Comparison of baseline molecular features of FLT3 WT and FLT3m cohorts showed that pts who had relapsed AML with a positive FLT3m had more frequent concomitant NRAS mutations compared with pts who had FLT3 WT AML at relapse (60% vs 5%; p=0.003). No significant difference was seen in the frequency of TP53 (49% vs. 20%; p=0.36), NPM1 (15% vs. 40%; p=0.19), DNMT3A (16% vs. 40%; p=0.21), KRAS (5% vs. 0%; p=1), or PTPN11 (3% v. 0%; p=1) mutations between the two cohorts, respectively. Among 13 pts with AML with emergent FLT3m, 12 had diploid cytogenetics at diagnosis, but only 6 maintained the diploid status at relapse. The remaining 6 pts developed karyotypic clonal evolution at relapse (complex, n=1; KMT2A rearrangement, n=1; trisomy 8, n=1; other alterations, n=3). We had paired baseline and relapse NGS performed in 5 of 13 pts with relapsed AML, among these AMLs acquired new mutations. Nine newly acquired mutations were detected in the following genes: NPM1 (n=1), KRAS (n=1), RUNX1 (n=1), IDH2 (n=1), DNMT3A (n=1), ZRSR2 (n=1), WT1 (n=2), and STAG2 (n=1). Two of 5 pts had AML with no mutations at baseline, and 1 pt had AML with the same mutation profile at baseline and relapse. The median OS after relapse was 5.3 months and 5.5 months in pts with WT vs. FLT3m AML, respectively (P=0.29) (Figure 1). FLT3 mutant at diagnosis Among 84 pts with FLT3m AML at diagnosis, 52 (62%) and 32 (38%) pts experienced relapse with FLT3m and WT AML, respectively. Comparison of baseline molecular features of FLT3 WT and FLT3m AML showed a trend towards a higher frequency of NPM1 (77% vs. 47%; p=0.09) and DNMT3A mutations (55% vs. 21%; p=0.08) in patients who experienced relapse with FLT3m AML compared with FLT3 WT AML. No difference in the frequency TP53 (0% vs. 23%; p=0.13), KRAS (0% vs. 14%; p=0.27), NRAS (14% vs. 9%; p=0.63) and PTPN11 (7% vs. 14%; p=1) mutations was observed among both cohorts, respectively. The median OS after relapse was 8.1 months vs. 3.9 months in pts with FLT3 WT vs. FLT3m AML, respectively (p=0.005) (Figure 2). Conclusion: Our data suggest that FLT3m are more likely to emerge at AML relapse with concomitant NRAS mutations and indicate that FLT3m testing should be performed at relapse, irrespective of FLT3status at diagnosis. It is common for the FLT3 status to change, either from mutant to WT or vice versa. FLT3 status has immediate and clinically important implications for selection of appropriate therapeutic agents in the setting of salvage therapy. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310108059 created "2022-11-30" @default.
• W4310108059 creator A5000531117 @default.
• W4310108059 creator A5000750846 @default.
• W4310108059 creator A5010786159 @default.
• W4310108059 creator A5020340537 @default.
• W4310108059 creator A5030500582 @default.
• W4310108059 creator A5039613360 @default.
• W4310108059 creator A5041470459 @default.
• W4310108059 creator A5049385583 @default.
• W4310108059 creator A5050041791 @default.
• W4310108059 creator A5050914134 @default.
• W4310108059 creator A5056317446 @default.
• W4310108059 creator A5059373442 @default.
• W4310108059 creator A5061026876 @default.
• W4310108059 creator A5065499641 @default.
• W4310108059 creator A5070528077 @default.
• W4310108059 creator A5074807429 @default.
• W4310108059 creator A5088307376 @default.
• W4310108059 creator A5091492845 @default.
• W4310108059 date "2022-11-15" @default.
• W4310108059 modified "2023-10-15" @default.
• W4310108059 title "Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)" @default.
• W4310108059 doi "https://doi.org/10.1182/blood-2022-169991" @default.
• W4310108059 hasPublicationYear "2022" @default.
• W4310108059 type Work @default.
• W4310108059 citedByCount "0" @default.
• W4310108059 crossrefType "journal-article" @default.
• W4310108059 hasAuthorship W4310108059A5000531117 @default.
• W4310108059 hasAuthorship W4310108059A5000750846 @default.
• W4310108059 hasAuthorship W4310108059A5010786159 @default.
• W4310108059 hasAuthorship W4310108059A5020340537 @default.
• W4310108059 hasAuthorship W4310108059A5030500582 @default.
• W4310108059 hasAuthorship W4310108059A5039613360 @default.
• W4310108059 hasAuthorship W4310108059A5041470459 @default.
• W4310108059 hasAuthorship W4310108059A5049385583 @default.
• W4310108059 hasAuthorship W4310108059A5050041791 @default.
• W4310108059 hasAuthorship W4310108059A5050914134 @default.
• W4310108059 hasAuthorship W4310108059A5056317446 @default.
• W4310108059 hasAuthorship W4310108059A5059373442 @default.
• W4310108059 hasAuthorship W4310108059A5061026876 @default.
• W4310108059 hasAuthorship W4310108059A5065499641 @default.
• W4310108059 hasAuthorship W4310108059A5070528077 @default.
• W4310108059 hasAuthorship W4310108059A5074807429 @default.
• W4310108059 hasAuthorship W4310108059A5088307376 @default.
• W4310108059 hasAuthorship W4310108059A5091492845 @default.
• W4310108059 hasConcept C104317684 @default.
• W4310108059 hasConcept C126322002 @default.
• W4310108059 hasConcept C143998085 @default.
• W4310108059 hasConcept C2778729363 @default.
• W4310108059 hasConcept C2910954276 @default.
• W4310108059 hasConcept C501734568 @default.
• W4310108059 hasConcept C54355233 @default.
• W4310108059 hasConcept C71924100 @default.
• W4310108059 hasConcept C86803240 @default.
• W4310108059 hasConcept C90924648 @default.
• W4310108059 hasConceptScore W4310108059C104317684 @default.
• W4310108059 hasConceptScore W4310108059C126322002 @default.
• W4310108059 hasConceptScore W4310108059C143998085 @default.
• W4310108059 hasConceptScore W4310108059C2778729363 @default.
• W4310108059 hasConceptScore W4310108059C2910954276 @default.
• W4310108059 hasConceptScore W4310108059C501734568 @default.
• W4310108059 hasConceptScore W4310108059C54355233 @default.
• W4310108059 hasConceptScore W4310108059C71924100 @default.
• W4310108059 hasConceptScore W4310108059C86803240 @default.
• W4310108059 hasConceptScore W4310108059C90924648 @default.
• W4310108059 hasIssue "Supplement 1" @default.
• W4310108059 hasLocation W43101080591 @default.
• W4310108059 hasOpenAccess W4310108059 @default.
• W4310108059 hasPrimaryLocation W43101080591 @default.
• W4310108059 hasRelatedWork W2007812119 @default.
• W4310108059 hasRelatedWork W2525843451 @default.
• W4310108059 hasRelatedWork W2734785385 @default.
• W4310108059 hasRelatedWork W2894770453 @default.
• W4310108059 hasRelatedWork W2897496508 @default.
• W4310108059 hasRelatedWork W2897566843 @default.
• W4310108059 hasRelatedWork W3016975799 @default.
• W4310108059 hasRelatedWork W3110187006 @default.
• W4310108059 hasRelatedWork W4220713447 @default.
• W4310108059 hasRelatedWork W4362394642 @default.
• W4310108059 hasVolume "140" @default.
• W4310108059 isParatext "false" @default.
• W4310108059 isRetracted "false" @default.
• W4310108059 workType "article" @default.